Revisit the practice of lymph node biopsy in patients diagnosed as ductal carcinoma in situ before operation: a retrospective analysis of 682 cases and evaluation of the role of breast MRI

Table 5 Univariate and multivariate for factors related to lymph node metastasis in patients with pre-operative biopsy diagnosed ductal carcinoma in situ

	Univariate analysis			Multivariate analysis
	Odds ratio	95% CI	P	Odds ratio	95% CI	P
Age	0.97	0.94–1	0.06
Pathology^a tumor size (cm) overall group	1.01	0.9–1.13	0.9
Pathology^a DCIS-IC invasive part tumor size (invasive, cm) excluding pure DCIS cases	1.32	1.1–1.59	< 0.01
MRI tumor size (cm)	1.21	1–1.42	0.02
Sonogram tumor size (cm)	1.8	1.4–2.3	< 0.01	1.93	1.23–3.03	< 0.01
Mammogram tumor size (cm)	1.78	1–3.09	0.04
Pathology gloss^b tumor size ( cm)	1.03	0.91–1.16	0.63
Pathology-DCIS-IC gloss^btumor size ( cm)	0.99	0.86–1.13	0.86
Pathology-pure DCIS gloss^b tumor size ( cm)	0.54	0.15–1.99	0.36
Post OP biopsy (IDC) VS DCIS	34.94	10.73–113.79	< 0.01	36.37	4.63–288.81	< 0.01
Grade (II, III)VS I	1.1	0.42–2.88	0.85
ER (positive) VS negative	0.61	0.33–1.11	0.1
PR (positive) VS negative	0.7	0.38–1.26	0.23
HER-2 (positive) VS negative	0.89	0.47–1.68	0.72
Ki -67 (> 20)VS ≦ 20	1.64	0.71–3.81	0.25
MRI lymph node metastasis (Y)VS N	4.08	1.82–9.18	< 0.01	2.2	0.83–5.83	0.11

MMG mammography guided biopsy, LN lymph node, SLNB sentinel lymph node biopsy, ALND axillary lymph node dissection, ND not done, OP operation, DCIS ductal carcinoma in situ, TNBC triple negative breast cancer, ER estrogen receptor, PR progesterone receptor, HER-2 human epithelial grow receptor type 2, N/A not available
^aPathology tumor size: in pure DCIS cases pathologic tumor size=DCIS tumor size, if containing invasive component then pathologic tumor size=invasive cancer tumor size
^bGross tumor size: invasive + non-invasive component tumor size

ISSN: 1477-7819